Alzheimer’s drug gantenerumab fails to slow decline in phase III clinical trial
Polio: Five things to know about this serious disease
15 November 2022Welcome home: Nutrient-enriched diets improve health of premature, underweight babies post-discharge
15 November 2022Alzheimer’s drug gantenerumab fails to slow decline in phase III clinical trial
The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.
